Date: April 11, 2021 Your Name: Gang Liu

Manuscript Title: Itaconate ameliorates methicillin-resistant Staphylococcus aureus-induced acute lung

injury through the Nrf2/ARE pathway Manuscript number (if known): ATM-21-1448

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	National Natural Science Foundation of China No. 81871518 National Natural Science Foundation of China No. 81901522 China Postdoctoral Science Foundation No. 2019M661730 China Postdoctoral Science Foundation No. 2020M671347 Natural Science Foundation of Jiangsu Province	

			T
		Natural Science	
		Foundation of Jiangsu	
		Province	
		No. BE2020634	
		Natural Science	
		Foundation of Jiangsu	
		Province	
		No. BK20191138	
		Fundamental Research	
		Funds for the Central	
		Universities	
		No. JUSRP11955	
		Top Talent Support	
		Program for Young and	
		Middle-aged People of	
		Wuxi Health Committee	
		No. BJ2020049	
		Wuxi Commission of	
		Health	
		No. T201824	
		I .	2C months
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony	THO ITE	
	cestimony		
7	Support for attending	None	
,		None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
	-		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10		None	
			i de la companya de
10	Leadership or fiduciary role in other board, society,	None	

	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

This study was supported by National Natural Science Foundation of China (No. 81871518 and 81901522), the China Postdoctoral Science Foundation (No. 2019M661730 and 2020M671347), the Natural Science Foundation of Jiangsu Province (No. BK20200602, BE2020634, and BK20191138), the Fundamental Research Funds for the Central Universities (No. JUSRP11955), the Top Talent Support Program for Young and Middle-aged People of Wuxi Health Committee (No. BJ2020049), and the Wuxi Commission of Health (No. T201824) .

Please place an "X" next to the following statement to indicate your agreement:

Date: April 11, 2021 Your Name: Yaxian Wu

Manuscript Title: Itaconate ameliorates methicillin-resistant Staphylococcus aureus-induced acute lung

injury through the Nrf2/ARE pathway Manuscript number (if known): ATM-21-1448

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	National Natural Science Foundation of China No. 81871518 National Natural Science Foundation of China No. 81901522 China Postdoctoral Science Foundation No. 2019M661730 China Postdoctoral Science Foundation No. 2020M671347 Natural Science Foundation of Jiangsu Province No. BK20200602	

			T
		Natural Science	
		Foundation of Jiangsu	
		Province	
		No. BE2020634	
		Natural Science	
		Foundation of Jiangsu	
		Province	
		No. BK20191138	
		Fundamental Research	
		Funds for the Central	
		Universities	
		No. JUSRP11955	
		Top Talent Support	
		Program for Young and	
		Middle-aged People of	
		Wuxi Health Committee	
		No. BJ2020049	
		Wuxi Commission of	
		Health	
		No. T201824	
		I .	2C months
		Time frame: past	36 MONTHS
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony	THO ITE	
	cestimony		
7	Support for attending	None	
,		None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
	-		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10		None	
			i de la companya de
10	Leadership or fiduciary role in other board, society,	None	

	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

This study was supported by National Natural Science Foundation of China (No. 81871518 and 81901522), the China Postdoctoral Science Foundation (No. 2019M661730 and 2020M671347), the Natural Science Foundation of Jiangsu Province (No. BK20200602, BE2020634, and BK20191138), the Fundamental Research Funds for the Central Universities (No. JUSRP11955), the Top Talent Support Program for Young and Middle-aged People of Wuxi Health Committee (No. BJ2020049), and the Wuxi Commission of Health (No. T201824) .

Please place an "X" next to the following statement to indicate your agreement:

Date: April 11, 2021 Your Name: Sihao Jin

Manuscript Title: Itaconate ameliorates methicillin-resistant Staphylococcus aureus-induced acute lung

injury through the Nrf2/ARE pathway Manuscript number (if known): ATM-21-1448

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	National Natural Science Foundation of China No. 81871518 National Natural Science Foundation of China No. 81901522 China Postdoctoral Science Foundation No. 2019M661730 China Postdoctoral Science Foundation No. 2020M671347 Natural Science Foundation of Jiangsu Province No. BK20200602	

	T	T .	T
		Natural Science	
		Foundation of Jiangsu	
		Province	
		No. BE2020634	
		Natural Science	
		Foundation of Jiangsu	
		Province	
		No. BK20191138	
		Fundamental Research	
		Funds for the Central	
		Universities	
		No. JUSRP11955	
		Top Talent Support	
		Program for Young and	
		Middle-aged People of	
		Wuxi Health Committee	
		No. BJ2020049	
		Wuxi Commission of	
		Health	
		No. T201824	26
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
0	testimony	None	
	testimony		
7	Company for attending	Nege	
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
	1		
9	Participation on a Data	None	
9		None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		

	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

This study was supported by National Natural Science Foundation of China (No. 81871518 and 81901522), the China Postdoctoral Science Foundation (No. 2019M661730 and 2020M671347), the Natural Science Foundation of Jiangsu Province (No. BK20200602, BE2020634, and BK20191138), the Fundamental Research Funds for the Central Universities (No. JUSRP11955), the Top Talent Support Program for Young and Middle-aged People of Wuxi Health Committee (No. BJ2020049), and the Wuxi Commission of Health (No. T201824) .

Please place an "X" next to the following statement to indicate your agreement:

Date: April 11, 2021 Your Name: Jiaojiao Sun

Manuscript Title: Itaconate ameliorates methicillin-resistant Staphylococcus aureus-induced acute lung

injury through the Nrf2/ARE pathway Manuscript number (if known): ATM-21-1448

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	National Natural Science Foundation of China No. 81871518 National Natural Science Foundation of China No. 81901522 China Postdoctoral Science Foundation No. 2019M661730 China Postdoctoral Science Foundation No. 2020M671347 Natural Science Foundation of Jiangsu Province	

			T
		Natural Science	
		Foundation of Jiangsu	
		Province	
		No. BE2020634	
		Natural Science	
		Foundation of Jiangsu	
		Province	
		No. BK20191138	
		Fundamental Research	
		Funds for the Central	
		Universities	
		No. JUSRP11955	
		Top Talent Support	
		Program for Young and	
		Middle-aged People of	
		Wuxi Health Committee	
		No. BJ2020049	
		Wuxi Commission of	
		Health	
		No. T201824	
		I .	2C months
		Time frame: past	36 MONTHS
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony	THO ITE	
	cestimony		
7	Support for attending	None	
,		None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
	-		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10		None	
			i de la companya de
10	Leadership or fiduciary role in other board, society,	None	

	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

This study was supported by National Natural Science Foundation of China (No. 81871518 and 81901522), the China Postdoctoral Science Foundation (No. 2019M661730 and 2020M671347), the Natural Science Foundation of Jiangsu Province (No. BK20200602, BE2020634, and BK20191138), the Fundamental Research Funds for the Central Universities (No. JUSRP11955), the Top Talent Support Program for Young and Middle-aged People of Wuxi Health Committee (No. BJ2020049), and the Wuxi Commission of Health (No. T201824) .

Please place an "X" next to the following statement to indicate your agreement:

Date: April 11, 2021 Your Name: Bin-Bin Wan

Manuscript Title: Itaconate ameliorates methicillin-resistant Staphylococcus aureus-induced acute lung

injury through the Nrf2/ARE pathway Manuscript number (if known): ATM-21-1448

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	National Natural Science Foundation of China No. 81871518 National Natural Science Foundation of China No. 81901522 China Postdoctoral Science Foundation No. 2019M661730 China Postdoctoral Science Foundation No. 2020M671347 Natural Science Foundation of Jiangsu Province No. BK20200602	

			T
		Natural Science	
		Foundation of Jiangsu	
		Province	
		No. BE2020634	
		Natural Science	
		Foundation of Jiangsu	
		Province	
		No. BK20191138	
		Fundamental Research	
		Funds for the Central	
		Universities	
		No. JUSRP11955	
		Top Talent Support	
		Program for Young and	
		Middle-aged People of	
		Wuxi Health Committee	
		No. BJ2020049	
		Wuxi Commission of	
		Health	
		No. T201824	
		I .	2C months
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony	THO ITE	
	cestimony		
7	Support for attending	None	
,		None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
	-		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10		None	
			i de la companya de
10	Leadership or fiduciary role in other board, society,	None	

	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

This study was supported by National Natural Science Foundation of China (No. 81871518 and 81901522), the China Postdoctoral Science Foundation (No. 2019M661730 and 2020M671347), the Natural Science Foundation of Jiangsu Province (No. BK20200602, BE2020634, and BK20191138), the Fundamental Research Funds for the Central Universities (No. JUSRP11955), the Top Talent Support Program for Young and Middle-aged People of Wuxi Health Committee (No. BJ2020049), and the Wuxi Commission of Health (No. T201824) .

Please place an "X" next to the following statement to indicate your agreement:

Date: April 11, 2021 Your Name: Jiru Zhang

Manuscript Title: Itaconate ameliorates methicillin-resistant Staphylococcus aureus-induced acute lung

injury through the Nrf2/ARE pathway Manuscript number (if known): ATM-21-1448

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	National Natural Science Foundation of China No. 81871518 National Natural Science Foundation of China No. 81901522 China Postdoctoral Science Foundation No. 2019M661730 China Postdoctoral Science Foundation No. 2020M671347 Natural Science Foundation of Jiangsu Province No. BK20200602	

			T
		Natural Science	
		Foundation of Jiangsu	
		Province	
		No. BE2020634	
		Natural Science	
		Foundation of Jiangsu	
		Province	
		No. BK20191138	
		Fundamental Research	
		Funds for the Central	
		Universities	
		No. JUSRP11955	
		Top Talent Support	
		Program for Young and	
		Middle-aged People of	
		Wuxi Health Committee	
		No. BJ2020049	
		Wuxi Commission of	
		Health	
		No. T201824	
		I .	2C months
		Time frame: past	36 MONTHS
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony	THO ITE	
	cestimony		
7	Support for attending	None	
,		None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
	-		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10		None	
			i de la companya de
10	Leadership or fiduciary role in other board, society,	None	

	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

This study was supported by National Natural Science Foundation of China (No. 81871518 and 81901522), the China Postdoctoral Science Foundation (No. 2019M661730 and 2020M671347), the Natural Science Foundation of Jiangsu Province (No. BK20200602, BE2020634, and BK20191138), the Fundamental Research Funds for the Central Universities (No. JUSRP11955), the Top Talent Support Program for Young and Middle-aged People of Wuxi Health Committee (No. BJ2020049), and the Wuxi Commission of Health (No. T201824) .

Please place an "X" next to the following statement to indicate your agreement:

Date: April 11, 2021

Your Name: Yingying Wang

Manuscript Title: Itaconate ameliorates methicillin-resistant Staphylococcus aureus-induced acute lung

injury through the Nrf2/ARE pathway Manuscript number (if known): ATM-21-1448

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	National Natural Science Foundation of China No. 81871518 National Natural Science Foundation of China No. 81901522 China Postdoctoral Science Foundation No. 2019M661730 China Postdoctoral Science Foundation No. 2020M671347 Natural Science Foundation of Jiangsu Province No. BK20200602	

			T
		Natural Science	
		Foundation of Jiangsu	
		Province	
		No. BE2020634	
		Natural Science	
		Foundation of Jiangsu	
		Province	
		No. BK20191138	
		Fundamental Research	
		Funds for the Central	
		Universities	
		No. JUSRP11955	
		Top Talent Support	
		Program for Young and	
		Middle-aged People of	
		Wuxi Health Committee	
		No. BJ2020049	
		Wuxi Commission of	
		Health	
		No. T201824	
		I .	2C months
		Time frame: past	36 MONTHS
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony	THO ITE	
	cestimony		
7	Support for attending	None	
,		None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
	-		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10		None	
			i de la companya de
10	Leadership or fiduciary role in other board, society,	None	

	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

This study was supported by National Natural Science Foundation of China (No. 81871518 and 81901522), the China Postdoctoral Science Foundation (No. 2019M661730 and 2020M671347), the Natural Science Foundation of Jiangsu Province (No. BK20200602, BE2020634, and BK20191138), the Fundamental Research Funds for the Central Universities (No. JUSRP11955), the Top Talent Support Program for Young and Middle-aged People of Wuxi Health Committee (No. BJ2020049), and the Wuxi Commission of Health (No. T201824) .

Please place an "X" next to the following statement to indicate your agreement:

Date: April 11, 2021 Your Name: Zhi-Qi Gao

Manuscript Title: Itaconate ameliorates methicillin-resistant Staphylococcus aureus-induced acute lung

injury through the Nrf2/ARE pathway Manuscript number (if known): ATM-21-1448

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	National Natural Science Foundation of China No. 81871518 National Natural Science Foundation of China No. 81901522 China Postdoctoral Science Foundation No. 2019M661730 China Postdoctoral Science Foundation No. 2020M671347 Natural Science Foundation of Jiangsu Province No. BK20200602	

			T
		Natural Science	
		Foundation of Jiangsu	
		Province	
		No. BE2020634	
		Natural Science	
		Foundation of Jiangsu	
		Province	
		No. BK20191138	
		Fundamental Research	
		Funds for the Central	
		Universities	
		No. JUSRP11955	
		Top Talent Support	
		Program for Young and	
		Middle-aged People of	
		Wuxi Health Committee	
		No. BJ2020049	
		Wuxi Commission of	
		Health	
		No. T201824	
		I .	2C months
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony	THO ITE	
	cestimony		
7	Support for attending	None	
,		None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
	-		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10		None	
			i de la companya de
10	Leadership or fiduciary role in other board, society,	None	

	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

This study was supported by National Natural Science Foundation of China (No. 81871518 and 81901522), the China Postdoctoral Science Foundation (No. 2019M661730 and 2020M671347), the Natural Science Foundation of Jiangsu Province (No. BK20200602, BE2020634, and BK20191138), the Fundamental Research Funds for the Central Universities (No. JUSRP11955), the Top Talent Support Program for Young and Middle-aged People of Wuxi Health Committee (No. BJ2020049), and the Wuxi Commission of Health (No. T201824) .

Please place an "X" next to the following statement to indicate your agreement:

Date: April 11, 2021 Your Name: Dan Chen

Manuscript Title: Itaconate ameliorates methicillin-resistant Staphylococcus aureus-induced acute lung

injury through the Nrf2/ARE pathway Manuscript number (if known): ATM-21-1448

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	National Natural Science Foundation of China No. 81871518 National Natural Science Foundation of China No. 81901522 China Postdoctoral Science Foundation No. 2019M661730 China Postdoctoral Science Foundation No. 2020M671347 Natural Science Foundation of Jiangsu Province No. BK20200602	

			T
		Natural Science	
		Foundation of Jiangsu	
		Province	
		No. BE2020634	
		Natural Science	
		Foundation of Jiangsu	
		Province	
		No. BK20191138	
		Fundamental Research	
		Funds for the Central	
		Universities	
		No. JUSRP11955	
		Top Talent Support	
		Program for Young and	
		Middle-aged People of	
		Wuxi Health Committee	
		No. BJ2020049	
		Wuxi Commission of	
		Health	
		No. T201824	
		I .	2C months
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony	THO ITE	
	cestimony		
7	Support for attending	None	
,		None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
	-		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10		None	
			i de la companya de
10	Leadership or fiduciary role in other board, society,	None	

	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

This study was supported by National Natural Science Foundation of China (No. 81871518 and 81901522), the China Postdoctoral Science Foundation (No. 2019M661730 and 2020M671347), the Natural Science Foundation of Jiangsu Province (No. BK20200602, BE2020634, and BK20191138), the Fundamental Research Funds for the Central Universities (No. JUSRP11955), the Top Talent Support Program for Young and Middle-aged People of Wuxi Health Committee (No. BJ2020049), and the Wuxi Commission of Health (No. T201824) .

Please place an "X" next to the following statement to indicate your agreement:

Date: April 11, 2021 Your Name: Shengpeng Li

Manuscript Title: Itaconate ameliorates methicillin-resistant Staphylococcus aureus-induced acute lung

injury through the Nrf2/ARE pathway Manuscript number (if known): ATM-21-1448

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	National Natural Science Foundation of China No. 81871518 National Natural Science Foundation of China No. 81901522 China Postdoctoral Science Foundation No. 2019M661730 China Postdoctoral Science Foundation No. 2020M671347 Natural Science Foundation of Jiangsu Province	

			T
		Natural Science	
		Foundation of Jiangsu	
		Province	
		No. BE2020634	
		Natural Science	
		Foundation of Jiangsu	
		Province	
		No. BK20191138	
		Fundamental Research	
		Funds for the Central	
		Universities	
		No. JUSRP11955	
		Top Talent Support	
		Program for Young and	
		Middle-aged People of	
		Wuxi Health Committee	
		No. BJ2020049	
		Wuxi Commission of	
		Health	
		No. T201824	
		I .	2C months
		Time frame: past	36 MONTHS
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony	THO ITE	
	cestimony		
7	Support for attending	None	
,		None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
	-		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10		None	
			i de la companya de
10	Leadership or fiduciary role in other board, society,	None	

	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

This study was supported by National Natural Science Foundation of China (No. 81871518 and 81901522), the China Postdoctoral Science Foundation (No. 2019M661730 and 2020M671347), the Natural Science Foundation of Jiangsu Province (No. BK20200602, BE2020634, and BK20191138), the Fundamental Research Funds for the Central Universities (No. JUSRP11955), the Top Talent Support Program for Young and Middle-aged People of Wuxi Health Committee (No. BJ2020049), and the Wuxi Commission of Health (No. T201824) .

Please place an "X" next to the following statement to indicate your agreement:

Date: April 11, 2021

Your Name: Qingfeng Pang

Manuscript Title: Itaconate ameliorates methicillin-resistant Staphylococcus aureus-induced acute lung

injury through the Nrf2/ARE pathway Manuscript number (if known): ATM-21-1448

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	National Natural Science Foundation of China No. 81871518 National Natural Science Foundation of China No. 81901522 China Postdoctoral Science Foundation No. 2019M661730 China Postdoctoral Science Foundation No. 2020M671347 Natural Science Foundation of Jiangsu Province No. BK20200602	

			T
		Natural Science	
		Foundation of Jiangsu	
		Province	
		No. BE2020634	
		Natural Science	
		Foundation of Jiangsu	
		Province	
		No. BK20191138	
		Fundamental Research	
		Funds for the Central	
		Universities	
		No. JUSRP11955	
		Top Talent Support	
		Program for Young and	
		Middle-aged People of	
		Wuxi Health Committee	
		No. BJ2020049	
		Wuxi Commission of	
		Health	
		No. T201824	
		I .	2C months
		Time frame: past	36 MONTHS
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony	THO ITE	
	cestimony		
7	Support for attending	None	
,		None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
	-		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10		None	
			i de la companya de
10	Leadership or fiduciary role in other board, society,	None	

	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

This study was supported by National Natural Science Foundation of China (No. 81871518 and 81901522), the China Postdoctoral Science Foundation (No. 2019M661730 and 2020M671347), the Natural Science Foundation of Jiangsu Province (No. BK20200602, BE2020634, and BK20191138), the Fundamental Research Funds for the Central Universities (No. JUSRP11955), the Top Talent Support Program for Young and Middle-aged People of Wuxi Health Committee (No. BJ2020049), and the Wuxi Commission of Health (No. T201824) .

Please place an "X" next to the following statement to indicate your agreement:

Date: April 11, 2021

Your Name: Zhiqiang Wang

Manuscript Title: Itaconate ameliorates methicillin-resistant Staphylococcus aureus-induced acute lung

injury through the Nrf2/ARE pathway Manuscript number (if known): ATM-21-1448

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	National Natural Science Foundation of China No. 81871518 National Natural Science Foundation of China No. 81901522 China Postdoctoral Science Foundation No. 2019M661730 China Postdoctoral Science Foundation No. 2020M671347 Natural Science	
		Foundation of Jiangsu Province No. BK20200602	

			T
		Natural Science	
		Foundation of Jiangsu	
		Province	
		No. BE2020634	
		Natural Science	
		Foundation of Jiangsu	
		Province	
		No. BK20191138	
		Fundamental Research	
		Funds for the Central	
		Universities	
		No. JUSRP11955	
		Top Talent Support	
		Program for Young and	
		Middle-aged People of	
		Wuxi Health Committee	
		No. BJ2020049	
		Wuxi Commission of	
		Health	
		No. T201824	
		I .	2C months
		Time frame: past	36 MONTHS
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony	THO ITE	
	cestimony		
7	Support for attending	None	
,		None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
	-		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10		None	
			i de la companya de
10	Leadership or fiduciary role in other board, society,	None	

	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

This study was supported by National Natural Science Foundation of China (No. 81871518 and 81901522), the China Postdoctoral Science Foundation (No. 2019M661730 and 2020M671347), the Natural Science Foundation of Jiangsu Province (No. BK20200602, BE2020634, and BK20191138), the Fundamental Research Funds for the Central Universities (No. JUSRP11955), the Top Talent Support Program for Young and Middle-aged People of Wuxi Health Committee (No. BJ2020049), and the Wuxi Commission of Health (No. T201824) .

Please place an "X" next to the following statement to indicate your agreement: